Scholarlink

Background <p>Programmed death ligand 1 (PD-L1) expression, assessed by the combined positive score (CPS), is an established predictive biomarker for first-line chemo-immunotherapy in metastatic triple-negative breast cancer (mTNBC). In routine practice, CPS testing is heterogeneous and its relationship with outcomes in later-line, sacituzumab govitecan (SG)-treated patients with mTNBC is not well described. We aimed to assess clinicopathological correlates of CPS and its association with survival in this cohort.</p> Methods <p>We conducted a retrospective, multicenter study within the Central European Breast Cancer Collaboration (CEBCC)-102 project. CPS was locally assessed by validated immunohistochemistry. Survival outcomes: overall survival (OS), post-metastatic survival (PMS), and metastasis-free interval, were assessed with the Kaplan–Meier method.</p> Results <p>Of 303 women from the Czech Republic, Poland, and Slovakia with mTNBC treated with SG in ≥ 2 line, 107 (35.3%) with available CPS results were included in this analysis. CPS was positive (≥ 10) in 51/107 patients (47.7%) without significant demographic or disease-specific differences. During a median follow-up of 40&#xa0;months, CPS-positive status may suggest worse outcomes in this cohort in multivariate analysis despite partial first-line chemo-immunotherapy exposure: OS 41.6 versus 67.7&#xa0;months (HR 2.2, 95% CI: 1.1–4.5, <i>p</i> = 0.027) and PMS 20.2 versus 27.1&#xa0;months (HR = 2.3, 95% CI: 1.2–4.2, <i>p</i> = 0.009).</p> Conclusions <p>In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

  • 期刊论文

  • 发表日期：

    2026年2月2日

查看全文
  • Karolina Winsko-Szczęsnowicz,
  • Małgorzata Pieniążek,
  • Anna Polakiewicz-Gilowska,
  • Marcin Kubeczko,
  • Miloš Holánek,
  • Miroslava Malejčíková,
  • Renáta Soumarová,
  • Hana Študentová,
  • Aleksandra Konieczna,
  • Agnieszka Młodzińska,
  • Justyna Żubrowska,
  • Maja Lisik-Habib,
  • Anika Pękala,
  • Daniel Krejčí,
  • Jan Šustr,
  • Iveta Kolářová,
  • Iwona Danielewicz,
  • Magdalena Szymanik-Resko,
  • Tomasz Ciszewski,
  • Lenka Rusinová,
  • Bogumiła Czartoryska-Arłukowicz,
  • Aleksandra Łacko,
  • Michał Jarząb,
  • Zuzana Bielčiková,
  • Renata Pacholczak-Madej,
  • Mirosława Püsküllüoğlu

摘要

Background

Programmed death ligand 1 (PD-L1) expression, assessed by the combined positive score (CPS), is an established predictive biomarker for first-line chemo-immunotherapy in metastatic triple-negative breast cancer (mTNBC). In routine practice, CPS testing is heterogeneous and its relationship with outcomes in later-line, sacituzumab govitecan (SG)-treated patients with mTNBC is not well described. We aimed to assess clinicopathological correlates of CPS and its association with survival in this cohort.

Methods

We conducted a retrospective, multicenter study within the Central European Breast Cancer Collaboration (CEBCC)-102 project. CPS was locally assessed by validated immunohistochemistry. Survival outcomes: overall survival (OS), post-metastatic survival (PMS), and metastasis-free interval, were assessed with the Kaplan–Meier method.

Results

Of 303 women from the Czech Republic, Poland, and Slovakia with mTNBC treated with SG in ≥ 2 line, 107 (35.3%) with available CPS results were included in this analysis. CPS was positive (≥ 10) in 51/107 patients (47.7%) without significant demographic or disease-specific differences. During a median follow-up of 40 months, CPS-positive status may suggest worse outcomes in this cohort in multivariate analysis despite partial first-line chemo-immunotherapy exposure: OS 41.6 versus 67.7 months (HR 2.2, 95% CI: 1.1–4.5, p = 0.027) and PMS 20.2 versus 27.1 months (HR = 2.3, 95% CI: 1.2–4.2, p = 0.009).

Conclusions

In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating.

Graphical abstract